Novel biologics in inflammatory bowel disease
- 30 June 2004
- journal article
- review article
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 33 (2) , 251-269
- https://doi.org/10.1016/j.gtc.2004.02.007
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- New biological therapies in inflammatory bowel diseaseBest Practice & Research Clinical Gastroenterology, 2003
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Infliximab in the Treatment of Crohn's Disease: A User's Guide for CliniciansAmerican Journal of Gastroenterology, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- The immunology of inflammatory bowel diseaseGastroenterology Clinics of North America, 2002
- Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodiesJournal of Immunological Methods, 1999
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Taming TNF: strategies to restrain this proinflammatory cytokineImmunology Today, 1997
- Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel diseaseGastroenterology, 1994